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Editorial 
The past decade has seen growing use of biologic drugs for the treatment of 
pediatric rheumatic diseases.1  The widest range of such treatments are used for juvenile 
idiopathic arthritis (JIA), although biologics are sometimes given in more refractory 
cases of juvenile systemic lupus erythematosus (JSLE), juvenile dermatomyositis 
(JDM) and vasculitis.  In this issue of the Journal, Al-Mayouf et al. report their use of 
biologic agents in children with rheumatic diseases at a tertiary hospital in Saudi Arabia 
between January 2001 and December 2011.2  A total of 134 patients were treated during 
this period, 70.1% with JIA, 12.7% with JSLE and 4.5% with vasculitis.  As expected 
for a cohort of predominantly JIA patients, the most frequently-used biologic drugs 
were those targeting tumour necrosis factor (anti-TNFs), including etanercept, 
adalimumab and infliximab.  The authors have described the use of biologics in various 
categories of JIA including polyarticular, psoriatic, “familial”, “ankylosing” and “IBD 
associated arthritis”.   
Most of the initial evidence for use of biologics derived from randomised 
controlled trials (RCTs) including patients with polyarticular JIA.1  In recent years, 
studies have been undertaken to investigate the use of these drugs in other categories of 
JIA including extended oligoarticular (eoJIA), psoriatic (PsJIA) and enthesitis-related 
arthritis (ERA).  A two-phase, randomised placebo-controlled withdrawal study of 
etanercept was undertaken in 41 patients with active ERA who had intolerance or 
inadequate response to initial standard treatment.3  In phase I, all patients received open-
label etanercept 0.8mg/kg body weight weekly for 24 weeks and the primary end point 
was at least 30% improvement in ACR Pedi criteria (ACR Pedi 30).  This was achieved 
in 38 patients (93%) who were then randomised in Phase II either to continue etanercept 
or placebo for a further 24 weeks.  The primary outcome of disease flare occurred in 9 
patients on placebo and 3 on etanercept (odds ratio 6.0, p=0.02).  The study represented 
35.6 patient-years (PY) exposure to etanercept with an adverse event (AE) rate of 4.5 
per year, most frequently upper respiratory tract infections (URTIs), adverse drug 
reactions and gastrointestinal infections.   
The efficacy and safety of etanercept has also been reported in ERA, eoJIA and 
PsJIA in an open-label study with a total of 122 subjects.4  At week 12 of treatment, 
achievement of JIA ACR Pedi 30 was 83.3%, 89.7% and 93.1% and of inactive disease 
was 16.7%, 11.9% and 6.9% in ERA, eoJIA and PsJIA respectively.  After long term 
follow-up at 96 weeks, achievement of JIA ACR Pedi 30 was 78.9%, 88.3% and 82.8% 
and of inactive disease was 21.1%, 33.3% and 24.1% in ERA, eoJIA and PsJIA 
respectively.5  Overall there were 139.5 AEs / 100 PY, most commonly infections, 
headache, pyrexia and diarrhoea.  There were no malignancies, active tuberculosis (TB), 
demyelinating diseases or death reported 
Forty-seven patients in the study of Al-Mayouf et al. were given adalimumab, 
mostly with polyarticular and systemic categories of JIA.  A double-blind, placebo-
controlled RCT has now provided evidence of efficacy of adalimumab in ERA.6  Forty-
six patients, age 6-18 years with active ERA, were randomised (31 to adalimumab at 
24mg/m2 every other week, 15 to placebo) for 12 weeks, with open-label treatment with 
adalimumab up to 192 weeks.  The primary efficacy endpoint was percentage change in 
active joint count between baseline and week 12: -62.6% in the adalimumab group 
versus -11.6% in the placebo group (p=0.039). At 52 weeks in the open-label phase, 
84.8% achieved ACR Pedi 30 and 60.9% ACR Pedi 90 responses.  The most frequent 
AEs were URTIs, injection site pain and increased alanine aminotransferase (ALT).  
Taking all these studies together, there is now evidence of efficacy of etanercept and 
adalimumab across a range of JIA categories with a similar AE profile as reported in 
other long term studies and no new safety signals. 
Uveitis associated with JIA is an important disease which is amenable to 
biologic treatment in cases of methotrexate intolerance or resistance.7  Al-Mayouf et al. 
reported only a single patient with uveitis, who was treated with etanercept, although it 
is not clear whether some of the patients given biologics for JIA had eye disease in 
addition to arthritis.  Current guidelines do not recommend etanercept as treatment for 
JIA-associated uveitis and the greatest evidence supports adalimumab as the first 
biologic drug.8  A double-blind, placebo-controlled RCT of adalimumab was stopped 
early due to efficacy after randomising 90 patients.9  Initial analysis of the primary 
endpoint (“time to treatment failure”) showed a positive effect in favour of adalimumab 
with a hazard ratio of 0.27 (95% confidence interval 0.13-0.52, p<0.0001).  AEs were 
seen in a similar proportion of patients in the treatment and placebo groups.  An open-
label study of subcutaneous tocilizumab for anti-TNF-refractory JIA-associated uveitis 
is now underway.10 
 
Systemic JIA (sJIA), which has a distinct immunobiology and is considered by 
many an autoinflammatory rather than autoimmune disease, was reported in 42 patients 
in the cohort of Al-Mayouf et al.  Most received anti-TNF treatment at some stage and 
many appear to have received at least two different biologic agents (including anakinra 
in 31% and tocilizumab in 21%).  The diverse range of biologic treatments used likely 
reflects the lack of a strong evidence base for management of sJIA during the reporting 
period.  Since the end point of this study in 2011, there has been a significant shift in the 
management of sJIA on the basis of evidence from RCTs of biologics targeting 
interleukin (IL)-1 (anakinra and canakinumab) and IL-6 (tocilizumab).1  A systematic 
review and meta-analysis of RCTs of anakinra, canakinumab, rilonacept and 
tocilizumab for treatment of sJIA has recently been published.11  This reported that all 
biologic agents had shown efficacy statistically significantly superior to placebo.  
Canakinumab and tocilizumab were more effective than rilonacept, however 
heterogeneity between the studies’ designs limited the quality of the evidence base for 
this comparison.  In terms of serious adverse events (SAEs), there were no differences 
between any of the four biologics and placebo. 
Importantly when discussing biologic drugs, which have a comparatively short 
history of use in childhood rheumatic diseases, Al-Mayouf et al. have reported AEs.  
The 134 children received a total of 273 different biologic treatments and experienced 
95 AEs, most frequently infusion- or injection-related reactions and infections in 18, 14 
and 23 patients respectively.  Although different types of AEs are detailed for individual 
biologics, there are no data on the cumulative drug exposure time or rates of AE per 
patient-year therefore comparison directly with other studies is not possible.  The data 
are presented attributing AEs to each biologic treatment, however since each drug was 
used for a range of different diseases there is potential for confounding by the 
underlying diagnosis.   
The safety of biologics in children with rheumatic diseases has been a focus of 
several long-term extension studies and national registries published recently.  In a 
study from Finland including 348 patients (total 1516 PY) receiving biologics for JIA or 
associated uveitis, the overall rate of AEs was 191/100 PY, most commonly mild 
infections, injection site or infusion reactions and increase in ALT.12  The rate of SAEs / 
100 PY was 11.4 on etanercept, 11.8 on infliximab, 10.1 on adalimumab, 15.7 on 
abatacept, 31.2 on tocilizumab and 87.5 on rituximab.  The median follow-up was 51 
months and no malignancies or TB were diagnosed.  Due to their immunosuppressive 
effects, infections are an ongoing concern in children receiving biologic agents.  By 
combining data from clinical trials, extension studies and registries, Horneff calculated 
the rate of serious infections per 100 PY: 1.28 on etanercept, 3.42 on infliximab, 1.42 
on adalimumab, 3.03 on golimumab, 1.33 on abatacept and 8.62 on tocilizumab.13 
Compared with JIA, there is a substantially smaller evidence-based for use of 
biologics in other pediatric rheumatic diseases, often based on case series or 
uncontrolled studies.  One exception is the randomised withdrawal trial of canakinumab 
for treatment of cryopyrin-associated periodic syndrome (CAPS), which includes 
chronic infantile neurological, cutaneous and articular (CINCA) syndrome and Muckle-
Wells syndrome (MWS).14  In the initial open-label treatment phase, 34 (97%) of 35 
patients had a complete response within 8 weeks after the first injection of 
canakinumab.  This treatment would not have been available to Al-Mayouf et al.  
However, their use of anakinra, which also targets the IL-1 pathway, in all 5 patients 
with CAPS is supported by several observational studies.15 
The most frequent use of a biologic drug, other than for JIA, in the cohort of 
patients from Saudi Arabia was rituximab for JSLE.  Evidence for its use mainly derives 
from controlled adult studies and case series in children.1  A recent retrospective study 
using the UK JSLE Cohort identified 63 patients who received 104 courses of rituximab 
with the most common indication being lupus nephritis.16  There were statistically 
significant improvements in biomarkers of disease activity and the dose of oral 
corticosteroids.   
Biologic drugs have already effected significant improvements in disease control 
in JIA, JIA-associated uveitis and CAPS.  On the horizon are more convenient routes of 
administration and drugs targeting novel biological pathways.  Currently trials are 
underway to investigate subcutaneous administration of tocilizumab and abatacept 
which have previously been shown to be efficacious when given intravenously for JIA.1  
Toficitinib, a Janus kinase inhibitor which can be administered orally, is undergoing 
investigation in patients with polyarticular-course JIA.  Patients 5-17 years old with 
active SLE are being recruited into an RCT of belimumab, a fully humanised 
monoclonal antibody against soluble B-lymphocyte stimulator (BLyS).  Alongside trials 
of novel biologic drugs, long-term extension studies and registries will be essential to 
monitor for adverse events, particularly in children who have their whole lives ahead of 
them. 
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